Aurobindo will be investing a further €6 million in its Malta plant, creating the largest analytical testing facilities in Europe, and quadruple its current testing capacity.
Works on the extension started last December and are expected to be completed by July.
Aurobindo was founded in India over 30 years ago, and now markets its products in over 125 countries, with annual revenues of €2 billion and 9,500 employees. Aurobindo Malta started operating in 2009 as a 100 per cent subsidiary of the Indian company with 11 employees, having made an investment of €4 million. Today, it has 60 full-time employees, having invested a further €6 million over the past five years.
The extension is expected to create 100 new jobs, increasing its annual testing capacity from 5,500 batches to 25,000.
Aurobindo’s European operations have now reached the €500 million mark, making it Europe’s largest Indian generic pharmaceutical manufacturer.